A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

[1] Lee JA(2011)Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy Expert Rev Pharmacoecon Outcome Res 11 325-341

[2] Shaheen M(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118-145

[3] Walke T(2004)Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER2-2/neu status Breast Cancer Res 6 R593-R600

[4] Daly M(2009)Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 1324-1333

[5] Wolff AC(2011)Testing for HER2 in breast cancer: a continuing evolution Patholog Res Int 2011 903202-689

[6] Hammond ME(2007)HER2 testing in the UK: consensus from a national consultation J Clin Pathol 60 685-1511

[7] Schwartz JN(2005)Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast Am J Surg Pathol 29 1505-324

[8] Hagerty KL(2007)PGDS, a novel technique combining chromogenic Appl Immunohistochem Mol Morphol 15 316-110

[9] Allred DC(2012) hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/ Am J Clin Pathol 137 102-3250

[10] Cote RJ(2001)) status in breast cancer Clin Cancer Res 7 3239-558

[1] Lee JA(2011)Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy Expert Rev Pharmacoecon Outcome Res 11 325-341

[2] Shaheen M(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118-145

[3] Walke T(2004)Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER2-2/neu status Breast Cancer Res 6 R593-R600

[4] Daly M(2009)Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 1324-1333

[5] Wolff AC(2011)Testing for HER2 in breast cancer: a continuing evolution Patholog Res Int 2011 903202-689

[6] Hammond ME(2007)HER2 testing in the UK: consensus from a national consultation J Clin Pathol 60 685-1511

[7] Schwartz JN(2005)Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast Am J Surg Pathol 29 1505-324

[8] Hagerty KL(2007)PGDS, a novel technique combining chromogenic Appl Immunohistochem Mol Morphol 15 316-110

[9] Allred DC(2012) hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/ Am J Clin Pathol 137 102-3250

[10] Cote RJ(2001)) status in breast cancer Clin Cancer Res 7 3239-558